Peginterferon beta-1a (Plegridy) Feedback Survey
Posted - 15 Jul 2015
The Canadian Agency for Drugs and Technologies in Health (CADTH) is conducting a drug review for an MS treatment called peginterferon beta-1a. Marketed as Plegridy(TM) by Biogen, this drug is a new formulation of interferon beta-1a that enables it to last longer in the body, reducing the dosing schedule. We need you to take part in this important initiative by providing feedback on the impact the drug has had on your MS, or the potential impact this drug could have on your MS or on the MS of someone you are providing care for. Submit your feedback by completing the MS Society's patient input survey. Your response will help to inform important health care decisions surrounding public coverage for MS treatments.
NARCOMS MS Research Effort Seeks Participants: MS Registry Enables Researchers to Find Solutions for People with MS
Article Date - 15 Mar 2015
Please see the article above regarding a survey for the North American Research Committee on Multiple Sclerosis (NARCOMS). NARCOMS is a global registry for Multiple Sclerosis (MS) research, treatment, and patient education. Their research program allows people with MS to expedite the research by volunteering information about one’s own experiences with MS.
There has been a good response to this survey, and consequently Dorothyanne has had to order more paper copies. If you would like a paper copy mailed to your home, here it is link through which you can directly request a form: http://www.narcoms.org/paperformrequest.
602-5 Horizon Court
Dartmouth, NS B3A 0C4